LZTS1 and prostate carcinoma: We analyzed LZTS1 ORF (exon 1–3) in a total of 220 cancers, from 72 primary esophageal cancers, 18 esophageal cancer cell lines, 24 primary prostate cancers, 3 prostate cancer cell lines, 39 primary breast cancers, 25 breast cancer cell lines, 8 primary ovarian cancers, 4 leukemic cell lines, 1 cervical cancer cell line [1] and 26 primary gastric cancers [5], regardless of the presence or absence of LZTS1 expression.